You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽升藥業(300485.SZ)擬與生物醫藥二期受讓綠竹生物15.385%股權
格隆匯 02-22 18:02

格隆匯 2 月 22日丨賽升藥業(300485.SZ)公佈,公司於近日與生物醫藥一期、北京亦莊二期生物醫藥產業投資基金(有限合夥)(“生物醫藥二期”)、綠竹生物及孔健、張琰平簽署了《股權轉讓協議》。

公司以現金出資的方式與生物醫藥二期受讓生物醫藥一期持有的綠竹生物15.385%的股權(對應認繳的註冊資本出資額為人民幣1964.5萬元);其中公司以2000萬元受讓生物醫藥一期持有綠竹生物3.077%的股權(對應認繳的註冊資本出資額為人民幣392.9萬元),生物醫藥二期以8000萬元受讓生物醫藥一期持有綠竹生物12.308%的股權(對應認繳的註冊資本出資額為人民幣1571.6萬元)。

綠竹生物與公司戰略發展方向具有較強協同性,公司與綠竹生物的合作符合公司以搭建研發創新平台、醫藥產業鏈創新平台、協作技術創新平台、產業資本平台為導向,深入佈局高端製劑、口服制劑及原料藥、現代中藥三大產業鏈板塊的戰略佈局。有利於推動公司醫藥產業鏈創新平台的升級打造,擴展抗體藥物及人用疫苗領域的產業佈局。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account